Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.
PYC Therapeutics Limited has announced the progression of its clinical trials for PYC-003, a drug candidate for Polycystic Kidney Disease (PKD). The Safety Review Committee has approved the escalation to the highest dose cohort in the Single Ascending Dose study, and dosing has commenced for PKD patients in Part B of the study. This advancement positions PYC to proceed to repeat dose studies in late 2025, potentially leading to a Phase 2/3 trial to support a New Drug Application.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no current treatment options. The company is engaged in three clinical-stage drug development programs, including PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD).
Average Trading Volume: 544,501
Technical Sentiment Signal: Buy
Current Market Cap: A$699.9M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.